Thanks pinch2020! nice finding.
So Novartis got whammy within 2 months: The US$2.9b acquired myelofibrosis drug Pelabresib halted in late October due to safety issue, and now the UCB's partnered Parkinson's asset fails phase 2 this week.
presumably Syntara's 5505 and 4782 are the perfect fits of these 2 holes in Novartis's pipeline. would be great If Gary can use his 8 years experience and connections in Novartis to bridge a deal between the 2 companies.
Just my speculation...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
-0.002(4.08%) |
Mkt cap ! $77.18M | |||
| Open | High | Low | Value | Volume |
| 4.9¢ | 5.0¢ | 4.7¢ | $331.1K | 6.935M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 287082 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.8¢ | 519872 | 9 |
View Market Depth
| Last trade - 14.47pm 23/06/2025 (20 minute delay) ? |
| SNT (ASX) Chart |